이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Kwangdong Pharm signs in-licensing deal for female sexual desire disorder drug

Collected: 2017.11.22

Distributed: 2017.11.23

Source: Go Direct

An investigational drug for hypoactive sexual desire disorder in premenopausal women will be introduced to South Korea as early as 2021.

On Wednesday, Kwangdong Pharmaceutical Co. announced it has signed a license agreement with U.S.-based Palatin Technologies, Inc. for exclusive rights to develop and commercialize the latter’s bremelanotide for female sexual dysfunction (FSD) indications in South Korea.

The prescription drug is administered subcutaneously on an as-needed basis under conditions of home use for the treatment of FSD in premenopausal women, according to Kwangdong Pharm.

Bremelanotide is just off a phase 3 study and a New Drug Application (NDA) is anticipated to be filed with the U.S. Food and Drug Administration (FDA) early next year. Kwangdong Pharm aims to launch the treatment in Korea in 2021 after regulatory approval.

By Kim Hye-soon and Minu Kim

List

Previous: Lotte Group chair sells off shares in Lotte Shopping ahead of next month trial

Next: Doosan Heavy wins $1 bn order to supply boilers, turbines to coal-fired power plant in S. Africa